A method of treating a solid in a mammal comprising the step of: administering a pharmaceutical acceptable amount of a thienotriazolodiazepine compound being represented by the following Formula (1): wherein R1 is alkyl having a carbon number of 1-4, R2 is a hydrogen atom； a halogen atom； or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R3 is a halogen atom； phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1 -4, alkoxy having a carbon number of 1-4 or cyano；— NR5— (CH2)m— R6 wherein R5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R6 is phenyl or pyridyl optionally substituted by a halogen atom； or -NR 7— CO— (CH2)n— R8 wherein R7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R8 is phenyl or pyridyl optionally substituted by a halogen atom, and R4 is — (CH2)a— CO— NH— R9 wherein a is an integer of 1-4, and R9 is alkyl having a carbon number of 1-4； hydroxyalkyl having a carbon number of 1-4； alkoxy having a carbon number of 1-4； or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or— (CH2)b— COOR10 wherein b is an integer of 1-4, and R10 is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.La présente invention concerne un procédé permettant de traiter une tumeur solide chez un mammifère comprenant les étapes consistant à : administrer une quantité pharmaceutiquement acceptable d'un composé thiénotriazolodiazépine réprésenté par la formule suivante (1) : dans laquelle R1 est un groupe alkyle ayant 1 à 4 atomes de carbone, R2 est un atome d'hydrogène, un atome d'halogène ou un groupe alkyle ayant 1 à 4 atomes de carbone facultativement substitué par un atome d'halogène ou un groupe hydroxyle, R3 est un atome d'halogène, un groupe phényle facultat
